endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Arti­va re­files for IPO three years af­ter orig­i­nal plans in a vast­ly dif­fer­ent en­vi­ron­ment

11 months ago
Financing
Startups

Al­ny­lam's big Phase 3 win; LGBTQ+ lead­ers chart­ing paths; Chevron over­turned; and more

11 months ago
Weekly

EMA's CHMP rec­om­mends 10 new drugs as Pierre Fab­re over­ac­tive blad­der med wins ap­proval

11 months ago
R&D
Pharma

Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

11 months ago
Pharma
FDA+

Fed­er­al grand ju­ry in­dicts Cas­sa­va col­lab­o­ra­tor for al­leged­ly de­fraud­ing NIH

11 months ago
Pharma
Law

CMS spells out how states can join new cell and gene ther­a­py ac­cess pi­lot

11 months ago
Pharma
FDA+

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

11 months ago
Pharma
FDA+

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

11 months ago
Pharma
Coronavirus

Rovi teas­es ac­qui­si­tion of­fers for its CD­MO unit po­ten­tial­ly worth €2B to €3B

11 months ago
Deals
Pharma

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

11 months ago
R&D

Savara’s $100M of­fer­ing; New biotech to test Ei­sai drug in Ph2

11 months ago
News Briefing

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

11 months ago
Cell/Gene Tx
FDA+

Au­toim­mune brain dis­ease start­up Ar­ialys gets new leader; In­tel­lia, Arv­inas ap­point CFOs

11 months ago
Peer Review

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

11 months ago
Financing
Startups

Lykos takes an­oth­er hit as ICER lays out 'in­suf­fi­cien­t' ev­i­dence for MD­MA-based treat­ment

11 months ago
R&D
Pharma

House pan­el ad­vances bill to al­low Medicare to cov­er obe­si­ty drugs

11 months ago
Pharma
FDA+

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

11 months ago
Deals
Pharma

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

11 months ago
Pharma
Law

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

11 months ago
R&D
Discovery

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

11 months ago
Pharma
Diagnostics

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025 

11 months ago
Manufacturing

SK Bio­science takes ma­jor­i­ty stake in CD­MO for $244M; Ex-Lon­za CEO joins Cy­ti­va

11 months ago
Manufacturing

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

11 months ago
Deals
R&D

Re­cur­sion’s $200M of­fer­ing; Sanofi in­vests $40M in Vig­il Neu­ro­science

11 months ago
News Briefing
First page Previous page 136137138139140141142 Next page Last page
A service from the Financial Times